Answer
ZTALMY (ganaxolone) is indicated as adjunctive treatment for epileptic seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder in patients aged 2 to 17 years.
Sources for this answer
- ZTALMY 50 mg/mL oral suspensionImmedica · emc · SmPC §4.1 Therapeutic Indications · Version 1Document updated
Sources checked